# Gland Pharma

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/gland-pharma
Canonical HTML page: https://getbiobrief.com/entity/gland-pharma

## Timeline

- **2026-03-24**: 2025 Annual Results — Fosun Pharma officially releases its full-year financial performance for 2025.
- **2025-Q4**: US FDA Approval — Key biosimilar assets receive final marketing authorization for the US market.
- **2025-Q2**: CAR-T Expansion — Yescarta receives expanded indication approval for second-line treatment in China.
- **2025-Q1**: ADC Platform Milestone — First internally developed ADC candidate enters Phase II clinical trials.

## Recent coverage (1 stories)

### Fosun Pharma 2025 Results: Innovation Revenue Surges as Global Footprint Expands
2026-03-24 17:03:06 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Fosun Pharma (2196.HK) reported its 2025 annual results, highlighting a significant shift toward innovative drug revenue and successful international commercialization of its biosimilar portfolio. The company's strategic focus on oncology and high-value therapeutics continues to drive growth despite a challenging global macroeconomic environment.
Full story: https://getbiobrief.com/story/fosun-pharma-2025-annual-results-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.